Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Editas Medicine Inc
EDITCurrent price
1.54 USD
-0.07 USD (-4.35%)
Last closed
1.56 USD
Company
www.editasmedicine.com
ISIN
US28106W1036
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
134 772 304 USD
Yield for 12 month
-71.32 %
1Y
3Y
5Y
10Y
15Y
EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Address: 11 Hurley Street, Cambridge, MA, United States, 02141
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3.75 USDP/E ratio
–Dividend Yield
–Current Year
+32 314 000 USD
Last Year
+78 123 000 USD
Current Quarter
+30 604 000 USD
Last Quarter
+61 000 USD
Current Year
+32 314 000 USD
Last Year
-99 528 000 USD
Current Quarter
+30 604 000 USD
Last Quarter
-1 538 000 USD
Key Figures EDIT
1 year
3 years
5 years
10 years
EBITDA
-233 111 008 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-35.52 %
PEG Ratio
–
Return On Equity TTM
-98.10 %
Wall Street Target Price
3.75 USD
Revenue TTM
32 314 000 USD
Book Value
1.62 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-49.00 %
Dividend Yield
–
Gross Profit TTM
-166 932 992 USD
Earnings per share
-2.88 USD
Diluted Eps TTM
-2.88 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics EDIT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History EDIT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation EDIT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.25
Price Sales TTM
4.17
Enterprise Value EBITDA
-1.36
Price Book MRQ
1.00
Financials EDIT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators EDIT
For 52 weeks
0.91 USD
6.69 USD
50 Day MA
1.49 USD
Shares Short Prior Month
13 149 670
200 Day MA
2.64 USD
Short Ratio
5.06
Shares Short
12 684 584
Short Percent
19.34 %
BeatStart